Food Supplement. Self-Care




Clinical trial

Regulatory approval


Product Launch



Intestinal biopsies from 80 subjects


450 subjects with CRC-compatible symptomatology

172 FIT + subjects from a screening population


327 FIT + subjects from a screening population

2.800 FIT +/- subjects from a screening population

PREVIPECT is a new prebiotic developed by GoodGut as a food supplement to maintain intestinal balance preventively or as a complement to restore a slight imbalance.

Current situation: problems and needs

  • The balance of intestinal ecosystem is essential for the correct execution of intestinal functions and maintain a state of well-being.
  • Factors such as an inadequate diet, stress situations, or the use of antibiotics can cause the decrease or loss of beneficial bacteria, altering the balance of the ecosystem.
  • In cases where the imbalance is not a disease consequence, it is usually referred to as transient dysbiosis.
  • Intestinal dysbiosis can not only lead to digestive discomforts such as bloating, diarrhea, or constipation but also fatigue, tiredness, headache, muscle pain, irritability, insomnia, etc.
  • Prebiotics are a class of functional foods that stimulate the growth of microorganisms in the intestinal tract, which are beneficial for the body, and can help to maintain or restore balance.
There is a need for tools able to maintain and restore intestinal balance effectively.

Our Proposal

The prebiotic of GoodGut with beneficial properties for intestinal health is a non-digestible fiber that has been developed to induce the selective growth of the protective bacteria and increase their immunoprotective activity, such as the production of volatile fatty acids. In addition, it provides several advantages compared to probiotics:
  • Increased treatment efficacy
  • Does not require refrigeration
  • Balances dysbiosis and increases most proactive anaerobic bacteria, which are not present in probiotics.

PREVIPECT has been tested in a pilot study with fecal samples from 18 patients with Inflammatory Bowel Disease, Irritable Bowel Syndrome, and health subjects, studying the effect of the prebiotic on the fecal microbiota, in collaboration with Hospital Universitari de Girona Dr. Josep Trueta. In addition, we completed theIn Vitro toxicity test. For more information, you can check the results published in the study here (Oliver L. et al, 2021).

In order to be able to administer the optimal amount to provide the greatest benefit, encapsulation assays will be carried out. With this, we plan to register the product in 2022.

Debido a la festividad del próximo día 6 y 8 de diciembre, esa semana no se realizarán recogidas de muestras.